Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 3/20 | 0.49 |
| ▸ | RXRB | P28702 | 3/20 | 0.49 |
| ▸ | RXRG | P48443 | 3/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 7/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14114732 | 0.84 | S1PR1 (0.39) | RXRARXRBRXRGS1PR1HTR2C | |
| SCHEMBL79415 | 0.81 | RXRA (0.52) | RXRARXRBRXRGMRGPRX4S1PR1 | |
| SCHEMBL79041 | 0.81 | RXRA (0.56) | RXRARXRBRXRGMRGPRX4S1PR1 | |
| SCHEMBL6812974 | 0.79 | CYP4F2 (0.54) | RXRARXRBRXRGMRGPRX4S1PR1 | |
| SCHEMBL18924486 | 0.79 | RXRA (0.50) | RXRARXRBRXRGMRGPRX4S1PR1 | |
| SCHEMBL20756090 | 0.78 | RXRA (0.54) | RXRARXRBRXRGMRGPRX4CTSS | |
| SCHEMBL13249285 | 0.78 | PTPN7 (0.39) | SLC6A4AR | |
| SCHEMBL3726426 | 0.77 | PTGER1 (0.54) | RXRARXRBRXRGMRGPRX4SLC6A4 | |
| SCHEMBL14453588 | 0.77 | MRGPRX4 (0.50) | RXRARXRBRXRGMRGPRX4S1PR1 | |
| SCHEMBL656838 | 0.77 | MRGPRX4 (0.50) | RXRARXRBRXRGMRGPRX4S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-20140296183-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140296183-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8809304-B2 | Amine compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-19 | — | — | US | disclosed |
| US-8809304-B2 | Amine compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-19 | — | — | US | disclosed |
| CN-101346346-B | Amine compound and use thereof for medical purposes | MITSUBISH TANABE PHARMA CORP | 2012-08-22 | — | — | CN | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-2168944-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-20090137530-A1 | Amine Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137530-A1 | Amine Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-05-28 | — | — | US | disclosed |
| CN-101346346-A | Amine compound and use thereof for medical purposes | MITSUBISH TANABE PHARMA CORP (JP) | 2009-01-14 | — | — | CN | disclosed |
| EP-1961734-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137530-A1 | Amine Compound and Use Thereof for Medical Purposes | HRH3, HRH2, HRH4 | RXRA 2471/4885RXRB 2398/4885RXRG 2190/4885 |
| US-20140296183-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | HRH3, HRH2, HRH4 | RXRA 2471/4885RXRB 2398/4885RXRG 2190/4885 |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | HLA-B, HLA-A, HLA-C | RXRA 2753/4885RXRB 2681/4885RXRG 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.